One under-$10 name that looks ready to trigger a near-term breakout trade is Oncothyreon (ONTY), a clinical-stage biopharmaceutical company focused primarily on the development of therapeutic products for the treatment of cancer. This stock has been beaten-up by the sellers so far in 2012, with shares down by close to 50%.
If you take a look at the chart for Oncothyreon, you'll see that this stock gapped down big in March from over $8 to under $5 a share on monster volume. Following that massive move lower, this stock has continued to downtrend with shares hitting a recent low of $3.35 a share. During that downtrend, shares of Oncothyreon have consistently made lower highs and lower lows, which is bearish technical price.
That said, the stock has started to reverse that trend recently with shares now making higher lows and higher highs. This stock is now trading within range of triggering a near-term breakout trade.>>22 Biopharma Stocks With Breakout Potential in 2012 Market players should now look for long-biased trades in ONTY if it can manage to trigger a breakout above some near-term overhead resistance at $3.99 to $4.20 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 683,880 shares. If we get that action soon, then ONTY could easily tag its next significant overhead resistance levels at $4.50 to $5.50 a share, or possibly even its 200-day moving average of $6.09 a share. If you like the look of ONTY here, then you could buy it off weakness and simply use a stop around $3.50 a share. You could also buy it off strength and get long once it takes out $3.99 to $4.20 with volume. Keep in mind that a move over $3.99 will put ONTY back above its 50-day moving average of $3.94 a share which would be bullish technical price action. Traders should consider any sustained trend above its 50-day for ONTY as bullish price action.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV